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Abstract 
A considerable number of studies have examined vitamin D status during pregnancy. 
Although data from observational studies denote vitamin D hypovitaminosis (deficiency or 
insufficiency) during pregnancy, data from interventional (supplementation) trials fail to 
reveal a significant impact on maternal and offspring health. The aim of this review was to 
critically appraise the methodology of the published trials in an attempt to explain the 
difference between observational and supplementation data. We found that this difference 
could be attributed to a variety of factors, namely: i) study design (lack of a specific outcome, 
enrolment of participants with low vitamin D concentrations only), ii) vitamin D expenditure 
(lack of determination of plasma half-life), iii) supplementation regimen (administration of a 
wide range of regimens, in terms of dose, bolus and form), iv) geographical characteristics 
(vitamin D needs could vary significantly within a country, particularly in areas with a wide 
range of latitude gradient), v) altered metabolism during pregnancy (vitamin D and calcium 
equilibrium are changed during pregnancy compared with the non-pregnant state) and vi) 
assay methodology (most studies report on a minority of vitamin D metabolites). All these 
parameters should be taken into consideration in the design of future vitamin D 
supplementation trials. 
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1. Introduction 
Pregnancy is a unique state in a woman’s life, characterized by a continuum of biologic 
events that enables tissue maturation, aiming for fetal adaptation to future environmental and 
nutritional influences (1, 2). On this critical time frame, several exogenous stimuli could 
affect maternal - neonatal syncytium and have an impact on pregnancy outcome, maternal 
health and future offspring development (1-3). A wide range of nutritional deficiencies have 
been recognized as a preventable cause of adverse health events, rendering scientific 
communities and health organizations worldwide to establish specific nutritional 
recommendations aiming for optimal fetal development (4). This suggested diet model, 
although very similar to a balanced healthy one suggested for most adults, incorporates 
recommendations, which apply to consumption of micronutrients and vitamins, which have 
been recognized to be of critical importance in protecting the developing fetus (4, 5). 
  
On that basis, data from observational studies during the last decade have suggested a 
potential adverse effect of maternal hypovitaminosis D during pregnancy on maternal and 
offspring health outcomes (6, 7). Gradually, interventional studies have been conducted, 
focusing on the potential beneficial effects of vitamin D supplementation on these outcomes. 
However, the majority of these studies failed to show any benefit from vitamin D 
supplementation during pregnancy. The reasons for absence of an agreement between data 
from observational and supplementation studies remain obscure. The aim of this review was 
to critically appraise the methodology of the published trials, in an attempt to explain why 
data from supplementation trials fail to reveal a significant impact on maternal and offspring 
health outcomes as date from observational studies are suggesting.  
 
2. Maternal outcomes  
Results for pre-eclampsia and gestational diabetes mellitus (GDM) fail to converge to a 
meaningful outcome, revealing the potential for systematic failures within the field. At that 
basis, this review included most representative studies on the field according to study sample 
and methodology (Table 1). 
 
2.1. Pre-eclampsia 
A series of supplementation studies have examined potential adverse maternal and pregnancy 
outcomes, mainly pre-eclampsia and GDM. Studies with pre-eclampsia risk reduction as their 
primary outcome can be divided into observational and randomized. A large, prospective 
observational trial from Norway (8) studied 23.423 nulliparous women, categorized into two 
groups, according to the use of vitamin D supplements before or during pregnancy. Vitamin 
D supplementation during pregnancy with 400 - 600 IU daily resulted in 27% risk reduction 
of pre-eclampsia [odds ratio (OR) 0.73, 95% confidence interval (CI) 0.58 - 0.92]. However, 
the beneficial effect of vitamin D intake should not be attributed to supplementation per se, 
due to the high intake of vitamin D-rich long n-3 fatty acids in the local diet. In another large, 
Hungarian study (9), routine vitamin D supplementation, either as a mono-therapy or 
contained in a multi-vitamin regimen, with a dose of 3,000 IU/week (average 400 IU/day) 
starting from the 20
th
 gestational week, resulted in a reduced risk of pre-eclampsia in a dose-
response manner. 
 
In the field of randomized trials, Marya et al. (10) in a placebo-controlled, non-blinded trial 
studied two groups of 200 pregnant women (supplementation group: 375 mg calcium
 
and 
1200 IU of vitamin D daily from the 20 - 24
th
 gestational week; non-supplementation group: 
normal diet) and found no statistical difference in the incidence of pre-eclampsia between 
them. The only blinded, supplementation study available so far (11) administered 400 
(control group), 2,000 or 4,000 IU of vitamin D3 daily during pregnancy. Cord blood 25-
hydroxy-vitamin D [25(OH)D] concentrations were 45.5 ± 25.3 nmol/l in the 2000 IU group 
and 66.3 ± 25.8 nmol/l in the 4000 IU group. Higher 25(OH)D concentrations did not alter 
cord blood calcium or phosphorus. The study suffered from a high dropout rate, while 
powered only for a biochemical endpoint. However, by combining all available randomized 
data so far, a reduced OR of pre-eclampsia is evident in supplemented women with a pooled 
OR of 0.66 (95% CI 0.52 - 0.83, p = 0.001) (12).        
 
2.2. Gestational diabetes mellitus 
Although some observational studies support an association between maternal 
hypovitaminosis D during pregnancy and the development of GDM (13-15), data from 
supplementation studies are limited. A double-blinded, randomized controlled trial (RCT) in 
54 women diagnosed with GDM reported an improvement in fasting glucose and 
Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) index after two doses of 
oral 50,000 IU vitamin D, given 21 days apart, compared with placebo (16). However, 
significant differences in these parameters were noted at baseline, making the results difficult 
to interpret. In an open label RCT of vitamin D supplementation in two groups of Pakistani 
women, 4,000 IU of vitamin D were administered compared to calcium
 
and ferrous sulphate 
supplementation (17). The obstetrical outcomes were identical in both groups. This effect 
was attributed to the inefficacy of the given vitamin D regimen to achieve normalization of 
maternal vitamin D status (only 15 % of pregnant women achieved concentrations above 30 
ng/ml), leaving the majority in the deficiency range. 
  
In an Australian double-blind controlled supplementation study (18), a cohort of 209 
pregnant women before 20
th
 gestational week were randomized in either 5,000 IU (n = 89) or 
400 IU (n = 90) of oral vitamin D3 daily, until delivery. Endpoints were maternal glucose 
concentrations in Oral Glucose Tolerance Test (OGTT, 26
th 
- 28
th
 gestational week), neonatal 
25(OH)D concentrations, obstetric and neonatal outcomes and assessment of maternal insulin 
resistance. Although an inverse association between baseline 25(OH)D and fasting and 2-h 
glucose concentrations was found in post hoc analysis, the 5,000 IU group failed to 
demonstrate significant differences in mean fasting, 2-h blood glucose concentrations and 
HOMA-IR, compared to the 400 IU group. Overall, all women in the 5,000 IU group which 
developed GDM (n = 7) manifested adequate vitamin D status at the time of diagnosis. 
However, this study was not adequately powered to detect a difference between groups in the 
incidence of GDM.  
 
In summary, as far as maternal outcomes are concerned, although supplementation studies 
homogeneously indicate a beneficial effect on the reduction of pre-eclampsia risk, the 
absence of pre-conception vitamin D values, the limited power and the heterogeneity in 
thresholds used do not allow for definitive conclusions to be drawn. In the case of GDM, risk 
reduction data do not indicate a beneficial effect, so far. 
 
3. Fetal outcomes 
Anthropometry at birth or during early life is the most studied extra-skeletal clinical outcome 
of maternal vitamin D supplementation. So far, only two (11,19) out of six RCTs (11,19-24) 
defined 25(OH)D concentrations as their primary outcome and had adequate sample size. The 
only study, which demonstrated effects on neonatal clinical parameters (20), was conducted 
in India, an area with profound vitamin D deficiency. Administration of two doses of 600,000 
IU vitamin D in the third trimester of pregnancy resulted in a significant increase in birth 
weight of the offspring, compared to the non-supplemented group. This study did not define a 
primary outcome parameter, used no placebo and reported no data on 25(OH)D 
concentrations.  
 
3.1. Anthropometry 
In an effort to assess post-partum beneficial effects of optimization of maternal vitamin D 
status in offspring linear growth, a randomized, double-blind, supplementation trial (24) 
(35,000 IU/week vs. placebo) during the first trimester of pregnancy evaluated longitudinally 
neonatal anthropometry from birth to 12 months of age. The primary analysis included 
evaluation of mean length-for-age Z-score based on international standards. At birth, no 
differences among the two groups were evident, whereas at one year of age, mean length-for-
age was higher in the supplemented group, in conjunction with an increase in longitudinal 
growth during early infancy, interpreted in an increase of 1.1 cm throughout the first year of 
life, after controlling for sex. A large-scale, supplementation study (11) treated 257 pregnant 
women with 400, 2,000 or 4,000 IU of vitamin D3 daily during pregnancy. Achieved cord 
blood 25(OH)D concentrations were 45.5 ± 25.3 nmol/l in the low-dose group and 66.3 ± 
25.8 nmol/l in the high-dose group. A positive association between vitamin D dose and 
neonatal weight percentile, as well as a negative association between 25(OH)D 
concentrations and premature labour and infection was evident. These results might have 
been biased by the small study sample (n = 162, supplemented until term) and the high 
percentage of maternal vitamin D deficiency (35%) in the group supplemented with 4,000 IU 
daily. 
 
3.2. Immune system 
The effect of maternal vitamin D supplementation on offspring immune profile remains 
controversial. In a large cohort of more than 5,000 young adults (25), supplementation with 
more than 2,000 IU vitamin D daily in the first year of life was found to be associated with an 
increased prevalence of allergic rhinitis. Although this trial centred on supplementation 
during infancy and not during pregnancy, it could comprise a spectrum of long-term effects 
of vitamin D equilibrium on immune regulation. This research question was the main 
objective in a RCT where 180 pregnant women were allocated randomly from 27
th
 
gestational week to either, single bolus of 200.000 IU per os or 800 IU d of ergocalciferol 
daily (26). No significant effect of maternal supplementation was evident on the risk of 
offspring wheeze, atopy (assessed by skin test) or lung function at 3 years of age. It has to be 
noted, however, that the supplemented groups demonstrated inadequate vitamin D status at 
both dosing regimens (daily dose: 26 nmol/l, bolus dose: 25 nmol/l), an effect that might 
influence potential beneficial effects of vitamin D supplementation. 
 
In summary, as far as fetal outcomes are concerned, supplementation studies indicate a 
potential beneficial effect on offspring anthropometry. However, several parameters 
regarding timing, duration and dose of supplementation regimen remain to be elucidated 
before incorporating this evidence into daily clinical practice. 
 
4. Why data from supplementation studies fail to reveal favourable clinical outcomes?  
Based on the data by the supplementation studies discussed above, a series of reasons can be 
implicated. These reasons are discussed in the following paragraphs and illustrated in Table 
2.  
 
4.1. Study design 
It could be argued that the link between maternal hypovitaminosis D and adverse outcomes is 
not causative and that decreased vitamin D concentrations are a consequence or a confounder, 
rather than a disease per se. However, recent data on cardiovascular disease (CVD) risk (27), 
suggest a causal association between serum 25(OH)D concentrations and CVD risk, as do 
most well-designed RCTs. The term “well-designed RCT” is of utmost importance in 
understanding the potential beneficial effects of vitamin D supplementation during 
pregnancy. As described recently by Heaney (28), a vitamin D RCT should focus on a 
specific outcome, enrol only participants with low 25(OH)D concentrations and supplement 
with appropriate doses and regimens of  vitamin D3. 
 
4.2. Vitamin D expenditure 
Theoretically, serum vitamin D concentrations are the result of endogenous production and 
dietary intake (29,30). As a consequence, the potential beneficial effects of vitamin D 
supplementation should be interpreted in the context of attained concentrations of serum 
25(OH)D and not just the dose administered. Vitamin D supplementation markedly differs 
from other interventions, where a pharmaceutical compound is given. In the former case, 
serum 25(OH)D concentrations are under the confounding contribution of newly synthesized 
25(OH)D, whereas  in the latter, serum / plasma concentrations depend on the administered 
dose (29). This phenomenon is of particular importance in defining the vitamin D dose-
response relationship in supplementation trials. Thus, incorporation of vitamin D expenditure 
parameters, such as 25(OH)D plasma half-life, could provide an additional insight to 
supplementation studies, by identifying vitamin D kinetics (e.g. storage and release from fat 
and muscle) (31).  
 
4.3. Supplementation regimen 
An ideal vitamin D supplementation trial in pregnancy would use a reference population, 
with different baseline vitamin D status, aiming at attaining sufficient serum 25(OH)D 
concentrations, in order to establish a “supplementation and result” relationship (28). 
Nevertheless, this outcome could be significantly affected by the regimen and dose of vitamin 
D used in each study. Since even a large bolus of 50,000 or 100,000 IU of vitamin D would 
rapidly (in a few days) be absorbed and undetectable from the serum (32). It has to be noted 
that several supplementation trials used this type of bolus administration, with a potential 
effect on their outcomes (19,23). In this context, the duration of supplementation could also 
play a role in maintaining adequate vitamin D concentrations. Although the optimal dosing 
and duration for specific outcomes remains to be defined, by supplying constant doses of 
vitamin D for 3 - 4 months, a steady state will be attained (33, 34). This is not the case in 
bolus regimens with monthly or weekly patterns of supplementation. The short duration of 
vitamin D supplementation during pregnancy (i.e. weeks or months) may also not be 
adequate to alter the pathogenetic pathways in which vitamin D is speculated to be involved, 
such as in pre-eclampsia and GDM states. Thus, supplementation before pregnancy and 
achievement of vitamin D sufficiency may be more effective than supplementation during 
pregnancy for both maternal and fetal outcomes. 
 
4.4. Geographical characteristics 
As vitamin D is generated by an environmental factor (sunshine exposure), it can be affected 
by geographical factors (35,36). Reports from Europe, USA and Africa indicate that 
populations from different countries share more common vitamin D-related characteristics 
than cohorts from the same country (37,38). This concept is further supported by Kimlin et al. 
(39), who assessed vitamin D data from seven USA locations. During eight months (March to 
October), no latitude gradient (from 18° to 44°N) of vitamin D was observed. In contrast, 
during cooler months (November to February) vitamin D was strongly determined by 
latitude. These observations indicate that vitamin D could vary significantly within a country, 
particularly in areas with a wide range of latitude gradient. Moreover, vitamin D status of 
immigrant populations in Europe was poor compared with that of the indigenous European 
populations (40), indicating that social and cultural habits are different as well. Indeed, the 
approach to vitamin D status taking into account specific geographical characteristics, such as 
latitude, ultra-violet B (UVB) radiation and microclimate, as well as the specific social and 
dietary habits, could minimize heterogeneity among studies. 
 
4.5. Metabolism during pregnancy 
Vitamin D and calcium equilibrium are altered during pregnancy compared with the non-
pregnant state (7). Pregnant women manifest extremely high concentrations of 1,25(OH)2D 
without evidence of hypercalcemia, whereas vitamin D-binding protein (VDBP) 
concentrations increase in response to high estrogen concentrations (41). VDBP is 
increasingly recognized as a vital parameter in the interpretation of vitamin D status (42). 
Recently, results from a large study in community-dwelling black Americans, demonstrated 
low concentrations of total 25(OH)D and VDBP compared to white population, resulting in 
similar concentrations of estimated bioavailable 25(OH)D (43). Although the assay 
methodology used in this was prone to overestimation of bio-available 25-hydroxyvitamin D 
by 2 to 2.5 times owing to underestimation of vitamin D–binding protein in black people, 
racial differences could theoretically explain these findings. Conversely, the increase in 
VDBP during pregnancy could decrease bioavailable vitamin D, albeit concentrations 
considered as normal according to current vitamin D criteria.  
  
These adaptive changes of vitamin D metabolism during pregnancy could interpret attained 
vitamin D concentrations, as optimal, although not. Interpreting bioavailable vitamin D 
concentrations in future trials in conjunction with VDBP concentrations could offer a new 
insight in the field. In addition, maternal vitamin D receptor (VDR) polymorphisms have 
been associated with an increase risk of GDM in Iranian population, as well as increased birth 
weight (44). 
 
4.6. Assay methodology 
Although the existence of various vitamin D forms, such as epimers, has been established, 
their clinical significance remains obscure. Most studies report on a minority of vitamin D 
metabolites, which are usually the circulating ones. The latter are convenient to be measured, 
but they are essentially inactive. Furthermore, recent data show that at least one epimer form 
has activity in vitro (45). In studies where both the active and circulating forms have been 
measured, there was no significant correlation between them. Indeed, a recent study has 
revealed that higher concentrations of the active form exist in diseases, such rheumatoid 
arthritis, and diabetes mellitus type 1 (46). 
 
In recent years, there have been considerable advances in techniques for vitamin D 
measurement (47,48). High quality assays for multiple vitamin D forms include liquid 
chromatography coupled to tandem mass spectrometry (LC-MS/MS) (49,50). With the 
development of more advanced assays, a thorough understanding of the interplay among the 
various vitamin D forms can be achieved. The accurate assay highlights a considerable 
proportion of vitamin D exists as epimers and there is a lack of correlation between the 
circulating and active forms. These results underscore the need for accurate measurements to 
appraise vitamin D status. The results, based on specific and accurate measurement, revealed 
that maternal characteristics and active forms of vitamin D, along with their epimers explain 
56% of neonatal vitamin D concentration (45). 
 
5. Conclusions 
Data from supplementation trials with vitamin D during pregnancy fail to reveal a significant 
impact on maternal and offspring health, at least in consistent way. Possible reasons for this 
fact may include: 
 
1. Study design: methodology flaws, such lack of a specific outcome and enrolment of 
participants with low 25(OH)D concentrations only. 
2. Vitamin D expenditure: lack of parameters that describe vitamin D expenditure, such 
as plasma half-life. 
3. Supplementation regimen: administration of a wide range of regimens, in terms of 
dose, bolus and form that prevent safe interpretation of study results. 
4. Geographical characteristics: vitamin D needs could vary significantly within a 
country, particularly in areas with a wide range of latitude gradient. 
5. Metabolism during pregnancy: vitamin D and calcium equilibrium are altered during 
pregnancy compared with the non-pregnant state. 
6. Assay methodology: most studies report on a minority of vitamin D metabolites. 
 
Supplementation with a biomolecule that also derives from endogenous production and 
undergoes significant transformation in order to accomplish its skeletal and extra-skeletal 
actions is a challenging task. By taking into account the whole spectrum of parameters that 
could affect vitamin D
 
homeostasis during pregnancy, it can be concluded that 
supplementation regimens should be specifically tailored on each population, taking into 
account parameters such the ones suggested by this study. 
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